Oxidative stress and antioxidant therapeutics in autism spectrum disorder: a biochemical and structure-activity relationship perspective.

This review looks at how oxidative stress (damage from harmful molecules in the body) may contribute to autism. Research shows people with autism often have higher levels of this type of damage. The authors examine various antioxidant supplements like N-acetylcysteine and vitamin E that might help reduce this damage and improve autism symptoms. While some studies show promise, more research is needed to determine the best doses and treatment approaches.

This comprehensive review examines the role of oxidative stress in autism spectrum disorder (ASD) and evaluates antioxidant therapeutics as potential interventions. The authors describe how oxidative stress, characterized by increased lipid peroxidation, protein oxidation, and DNA damage, contributes to ASD pathophysiology through synaptic dysfunction, neuroinflammation, and disrupted neuronal signaling. The review analyzes promising antioxidant compounds including N-acetylcysteine, glutathione precursors, coenzyme Q10, vitamin E, and polyphenols, examining their structure-activity relationships that determine therapeutic efficacy. Key functional groups like thiols, phenolic hydroxyls, and quinone moieties are identified as important for free radical scavenging and neuroprotective properties.

The review highlights the need for better understanding of optimal dosing, treatment duration, and combination strategies for antioxidant interventions in ASD.

While oxidative stress appears consistently elevated in ASD, antioxidant therapeutics require further investigation to establish evidence-based protocols. Current evidence suggests potential benefits but lacks standardized treatment approaches, highlighting the need for rigorous clinical trials to determine safety, efficacy, and optimal implementation strategies.

As a narrative review, findings are limited by the quality and selection of included studies. The abstract notes that optimal dosing, treatment duration, and combinatorial strategies remain poorly characterized, indicating significant gaps in current evidence.

Autism spectrum disorder is a multifaceted neurodevelopmental disorder that involves impaired social interaction, communication challenges, and repetitive behavior. The developing evidence emphasizes a key pathophysiological role for oxidative stress in ASD, which is initiated by an imbalance between ROS generation and antioxidant defense mechanisms. Increased levels of lipid peroxidation, protein oxidation, and DNA damage have been repeatedly found in ASD patients, indicating generalized oxidative damage and mitochondrial impairment. Redox homeostasis disruption is responsible for synaptic dysfunction, neuroinflammation, and disrupted neuronal signaling, worsening the fundamental symptoms of ASD.

In this regard, antioxidant therapeutics have attracted a great deal of attention as putative modulators of oxidative stress and neuroinflammation in ASD. Promising candidates such as N-acetylcysteine, glutathione precursors, coenzyme Q10, vitamin E, and polyphenols have been found to be potentially effective against oxidative damage and enhancing behavioral outcomes. The therapeutic potency of such compounds is directly related to their structure-activity relationships, which control their antioxidant activity, bioavailability, and blood-brain barrier permeability. SAR studies have revealed key functional groups, such as thiols, phenolic hydroxyls, and quinone moieties, which increase the free radical scavenging activity and neuroprotective properties of these compounds.

In spite of promising preclinical and clinical outcomes, the best dosing, treatment duration, and combinatorial strategies for antioxidant treatments in ASD are poorly characterized. In this review, the biochemical basis of oxidative stress in ASD is examined, the mechanistic understanding of antioxidant-based interventions is assessed, and the structure-activity relationships that dictate their therapeutic value are discussed. Clarifying these molecular complexities will facilitate the development of more potent and targeted antioxidant therapies, bringing new hope for controlling ASD-related oxidative pathologies.